title: Prediction of tamoxifen outcome by genetic variation of CYP2D6 in post-menopausal women with early breast cancer.
abstract: The question of whether genetic polymorphisms of CYP2D6 can affect treatment outcome in patients with early post-menopausal oestrogen receptor (ER)-positive breast cancer has been a matter of debate over the past few years. In this article we revisit the hypothesis of CYP2D6 being a potential tamoxifen outcome predictor and provide detailed insight into the ongoing controversy that prevented the CYP2D6 marker from being accepted by the scientific and clinical community. We summarize the available pharmacokinetic, pharmacodynamic and pharmacogenetic evidence and resolve the controversy based on the recognized methodological and statistical issues. The cumulative evidence suggests that genotyping for CYP2D6 is clinically relevant in post-menopausal women. This is important, because the clarification of this issue has the potential to resolve a clinical management question that is relevant to hundreds of thousands of women diagnosed with ER-positive breast cancer each year, who should not be denied effective endocrine therapy.
authors.affiliation: Dr Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany; University Tuebingen, Tuebingen.
authors.forename: Hiltrud
authors.initials: H
authors.lastname: Brauch
authors.forename: Matthias
authors.initials: M
authors.lastname: Schwab
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000493:pharmacokinetics / Q000627:therapeutic use*; D054316:Biomarkers, Pharmacological; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics*; D005260:Female; D005820:Genetic Testing / Q000379:methods; D005838:Genotype; D006801:Humans; D010597:Pharmacogenetics; D011110:Polymorphism, Genetic; D017698:Postmenopause / Q000235:genetics / Q000378:metabolism*; D013629:Tamoxifen / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D018931:Antineoplastic Agents, Hormonal; D054316:Biomarkers, Pharmacological; D013629:Tamoxifen; D019389:Cytochrome P-450 CYP2D6
keywords: CYP2D6; breast cancer; personalized medicine; pharmacogenetics; poor metabolizer; tamoxifen
references.citation: Clin Pharmacol Ther. 2001 Mar;69(3):89-95
references.pmid: 11240971
references.citation: Cancer Res. 2000 Jun 1;60(11):2836-9
references.pmid: 10850424
references.citation: J Clin Oncol. 2010 Aug 10;28(23):3784-96
references.pmid: 20625130
references.citation: Science. 2013 Mar 29;339(6127):1563-6
references.pmid: 23539596
references.citation: J Clin Oncol. 2005 Dec 20;23(36):9312-8
references.pmid: 16361630
references.citation: J Natl Cancer Inst. 2012 Mar 21;104(6):441-51
references.pmid: 22395644
references.citation: Clin Pharmacol Ther. 2011 May;89(5):718-25
references.pmid: 21430657
references.citation: Breast Cancer Res Treat. 2013 Jul;140(2):363-73
references.pmid: 23842856
references.citation: Breast Cancer Res Treat. 2004 May;85(2):151-9
references.pmid: 15111773
references.citation: Steroids. 2007 Nov;72(13):829-42
references.pmid: 17765940
references.citation: Clin Pharmacol Ther. 2011 May;89(5):708-17
references.pmid: 21451508
references.citation: Expert Rev Mol Diagn. 2013 May;13(4):349-65
references.pmid: 23638818
references.citation: Clin Cancer Res. 2010 Sep 1;16(17):4468-77
references.pmid: 20515869
references.citation: Pharmacol Ther. 2013 Apr;138(1):103-41
references.pmid: 23333322
references.citation: Cancer Res. 1986 Mar;46(3):1521-5
references.pmid: 3943109
references.citation: Br J Cancer. 2008 Aug 19;99(4):616-21
references.pmid: 18665165
references.citation: Cancer Chemother Pharmacol. 2005 May;55(5):471-8
references.pmid: 15685451
references.citation: Clin Cancer Res. 2013 Jan 15;19(2):500-7
references.pmid: 23213055
references.citation: J Natl Cancer Inst. 2012 Aug 22;104(16):1263-4; author reply 1266-8
references.pmid: 22851268
references.citation: Cancer Res. 2009 Feb 15;69(4):1243-54
references.pmid: 19208829
references.citation: Nature. 2012 Oct 4;490(7418):61-70
references.pmid: 23000897
references.citation: Lancet. 2005 May 14-20;365(9472):1687-717
references.pmid: 15894097
references.citation: Clin Cancer Res. 2001 Apr;7(4):876-82
references.pmid: 11309336
references.citation: Cancer Res. 1997 Aug 15;57(16):3402-6
references.pmid: 9270005
references.citation: J Clin Oncol. 2011 Aug 20;29(24):3232-9
references.pmid: 21768473
references.citation: Lancet Oncol. 2008 Jan;9(1):45-53
references.pmid: 18083636
references.citation: J Natl Cancer Inst. 2012 Mar 21;104(6):452-60
references.pmid: 22395643
references.citation: J Natl Cancer Inst. 2005 Jan 5;97(1):30-9
references.pmid: 15632378
references.citation: Pharmacogenetics. 2001 Oct;11(7):573-85
references.pmid: 11668217
references.citation: J Clin Oncol. 2013 Jan 10;31(2):176-80
references.pmid: 23091108
references.citation: J Clin Oncol. 2013 Jul 20;31(21):2755-6
references.pmid: 24040664
references.citation: JAMA. 2009 Oct 7;302(13):1429-36
references.pmid: 19809024
references.citation: Lancet. 2013 Mar 9;381(9869):805-16
references.pmid: 23219286
references.citation: Eur J Cancer. 2008 Jan;44(1):30-8
references.pmid: 18068350
references.citation: Clin Cancer Res. 2009 Jan 1;15(1):15-21
references.pmid: 19118028
references.citation: Clin Chem. 2009 Oct;55(10):1770-82
references.pmid: 19574470
references.citation: Pharmacogenetics. 1998 Feb;8(1):15-26
references.pmid: 9511177
references.citation: Curr Oncol Rep. 2010 Jan;12(1):7-15
references.pmid: 20425602
references.citation: J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75
references.pmid: 15159443
references.citation: J Natl Cancer Inst. 2012 Aug 22;104(16):1264; author reply 1266-8
references.pmid: 22851270
references.citation: Cancer Res. 2009 Mar 1;69(5):1722-7
references.pmid: 19244106
references.citation: Br J Clin Pharmacol. 2012 Oct;74(4):698-721
references.pmid: 22591598
references.citation: Lancet Oncol. 2009 Aug;10(8):825-33
references.pmid: 19647203
references.citation: Nat Rev Cancer. 2009 Aug;9(8):576-86
references.pmid: 19629072
references.citation: Eur J Cancer. 2009 Sep;45(13):2274-83
references.pmid: 19592233
references.citation: Genes Chromosomes Cancer. 2008 Dec;47(12):1049-66
references.pmid: 18720524
references.citation: J Clin Oncol. 2007 Feb 10;25(5):486-92
references.pmid: 17200148
references.citation: J Natl Cancer Inst. 2012 Aug 22;104(16):1265-6; author reply 1266-8
references.pmid: 22851267
references.citation: Clin Pharmacol Ther. 2006 Jul;80(1):61-74
references.pmid: 16815318